Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

MGC Pharma (ASX: MXC) down 35% - capital reconstruction and share issue to blame

There’s been both a share issue and a share consolidation, the end result being this 35% fall.

Update : 02 Nov 2023, 02:05 PM

MGC Pharmaceuticals (ASX: MXC) (LON: MXC) shares are down 35% today. This is the end result of the considerable work that’s been done on the capital structure of the company. This did have to be done as MGC simply was not sustainable without something being done. What was done was a 1 for 1,000 (yes, thousand) share consolidation or reverse stock split, plus a capital raise. The end result is that MGC Pharma is now funded through the next stage of its varied testing programs. That doesn’t mean that there will be value at the end of them but at least it will be possible to get there. 

We predicted something like this at MGC Pharma: “The MXC accounts show why.The company's losing $8 million a half year. It has under $2 million in cash. Yes, there are other assets but not enough to provide a significant runway. This is not the approval of a patented drug, where production costs are minimal, so that $2 million contract, or any other, does not flow through near directly to the bottom line. This is something that has to be sold, with all of the costs that implies.

“This approval is obviously beneficial. But it's not one of those Hail Mary passes that solves everything. Any really substantial move upwards in MXC is highly likely to be met by a capital raise. That might well put a cap on any such price move.”

Something did have to be done. There was a small and mild capital raise (which was even so nastily dilutive) over the summer and now this.

MGC Pharmaceuticals share price from Google Finance

That chart there is showing just the effects of the consolidation. The fall from the share issue is best seen on the ASX site.

The details of the fundraise: “MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company) a European based pharmaceutical company specialising in the production and development of innovative medicines for unmet medical needs, is pleased to announce that following shareholder approval for a new share placement secured at the Company's General Meeting on 25th October 2023 (Placement), the Company confirms that it has received binding commitments from sophisticated and professional investors (Investors) to subscribe for US$7.9 million of new shares under the Placement, at an issue price of US$0.255 (A$0.40)[1] per share (on a post-Consolidation basis).”

If the post consolidation price is 70 cents and the issuance is at 25 cents then yes, we can see why the price has fallen. This then confirms that: “Further to the Announcements, the Company confirms that on completion of the Consolidation (anticipated to be finalised on 2 November 2023), the Company will have 4,430,491 Shares in issue, each with one voting right. Therefore, on 2 November 2023, the total number of Shares in issue and voting rights will be 4,430,491 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.  Following the completion of the Placement (anticipated to be finalised on 7 November 2023), the Company will have 35,430,491 ordinary shares in issue, each with one voting right. Therefore, the Company's total number of shares in issue and voting rights will be 35,430,491.” Post issuance the original shareholders have a little over 10% of the expanded capital base. That’s sure some dilution there.

Hey, that’s what had to be done to refinance the company. But as we said back in the spring, a recapitalisation was definitely going to have to be done.

Top Brokers